- New financing enabling the Firm to increase its monetary visibility till the tip of Q2 2021
- Capital enhance carried out on the closing worth on February 6, 2020 with out low cost
- Capital enhance subscribed by BVF Companions L.P., New Enterprise Associates (NEA), Novo Holdings A / S and Sofinnova Companions
Daix (France), February 7, 2020 – Inventiva (Euronext: IVA), a biopharmaceutical firm specializing within the scientific growth of small molecules administered orally for the remedy of illnesses within the fields of fibrosis, lysosomal overload and oncology, at present publicizes the success the completion of a capital enhance of 15 million euros subscribed by a few of its current principal shareholders, BVF Companions LP, NEA, Novo Holdings A / S and Sofinnova Companions. The share capital enhance was carried out on the closing worth on February 6, 2020 with out low cost.
Frédéric Cren, Chairman and CEO and co-founder of Inventiva, commented: “We’re more than happy with the success of this capital enhance which was carried out at market worth and which permits us to increase our monetary visibility till the tip of the second quarter 2021. This operation comes after a second semester 2019 which could be very wealthy in scientific advances for Inventiva, with particularly the tip of affected person recruitment in our Part IIb scientific research with lanifibranor in NASH, the constructive outcomes of the Part IIa scientific research with odiparcil in MPS VI or the launch, sooner than anticipated, of the scientific research with ABB-157 in sufferers with psoriasis by our accomplice AbbVie. Because of the renewed confidence of our principal traders, BVF Companions L.P., NEA, Novo Holdings A / S and Sofinnova Companions and this a couple of months from the outcomes of our scientific research in NASH, we’re coming into 2020 with nice confidence and bolstered monetary means to proceed the scientific growth of lanifibranor and odiparcil, our two key drug candidates. “
Causes for the problem and use of the proceeds of the problem
The gross proceeds of the transaction amounted to 15 million euros. It is going to complement the present monetary assets of the Firm and can basically assist finance:
- the completion of the NATIVE Part IIb scientific research evaluating lanifibranor in non-alcoholic steatohepatitis (NASH) and the preparatory parts for the launch of Part III;
- the continued scientific growth of odiparcil within the remedy of kind VI mucopolysaccharidosis (MPS VI), together with the launch of the SAFE-KIDDS Part I / II scientific research in kids;
- the continuation of the YAP TEAD oncology program till the choice of a drug candidate.
Inventiva believes that this capital enhance will enhance the monetary visibility of the Firm and convey it from the center of the primary quarter 2021 to the tip of the second quarter 2021.
Important key steps anticipated
- Presentation of the outcomes of the Part IIa iMProveS scientific trial evaluating odiparcil within the remedy of MPS VI on 16th Annual WORLDSymposiumTM, Orlando, February 12, 2020;
- Publication of the outcomes of the NATIVE Part IIb scientific research evaluating lanifibranor within the remedy of NASH, 1st semester 2020;
- Launch of the SAFE-KIDDS Part I / II scientific trial in kids in MPS VI, deliberate for the tip of the 12 months.
Important options of the capital enhance
The Inventiva Board of Administrators, making use of the delegation of authority conferred on it below the fifth decision of the final assembly of shareholders of January 18, 2019 (capital enhance with cancellation of preferential subscription rights to the revenue of classes of individuals assembly particular traits) and in accordance with Article L. 225-138 et seq. of the French Industrial Code, determined at present to proceed with a capital enhance within the quantity of 15 million euros , by issuance of three,778,338 new shares with a nominal worth of 1 euro cent (€ Zero.01) every (the “ New Actions “) For a subscription worth of three.97 euros every (situation premium included) (the” Improve in capital “).
BVF Companions LP, NEA, Novo Holdings A / S and Sofinnova Companions, current shareholders of Inventiva and specialised within the well being and biotechnologies sector, renewed their confidence and took part within the capital enhance, persevering with to strengthen the shareholding construction of the Firm.
Lucy Lu, everlasting consultant of Sofinnova, additionally a member of the Board of Administrators, didn’t take part within the vote on the Board's resolution at present.
The subscription worth for New Shares set at three.97 euros equal to the closing worth on February 6, 2020, represents a premium of Zero.23% in comparison with the common weighted by the volumes of the Firm's share worth on the regulated market of Euronext in Paris throughout the assembly of February 6, 2020, in accordance with the 5th decision of the final assembly of shareholders of January 18, 2019.
Following the settlement-delivery operations scheduled for February 11, 2020, the share capital of Inventiva will quantity to 306,877.50 euros divided into 30,687,750 shares. The New Shares shall be assimilated to the present shares of the Firm and shall be admitted to buying and selling on the regulated market of Euronext in Paris below the quantity ISIN FR0013233012.
A request for admission of the brand new bizarre shares to be issued inside the framework of the capital enhance on the regulated market of Euronext Paris shall be made in accordance with an admission prospectus topic to the approval of the Autorité des Marchés Financiers ( the ” AMF “) And together with (i) the common registration doc that shall be filed with the AMF on February 7, 2020, and (ii) a Transaction Observe, together with (iii) a abstract of the prospectus. As of the submitting of the common registration doc with the AMF, copies of the common registration doc shall be obtainable freed from cost on the registered workplace of the Firm. The admission prospectus shall be printed on the AMF web site (www.amf-france.org).
Impression of the problem on the distribution of capital
The New Shares signify 12% of the variety of shares excellent after the Capital Improve. Thus, a shareholder holding 1% of the capital issued earlier than the operation will maintain Zero.88% of the capital on the finish of the operation.
Breakdown of share capital on the finish of the Capital Improve
The reader is invited to check with part 9.2 “Impression of the problem on the shareholder's state of affairs“of the Working Observe to be permitted by the AMF at present and wherein the shareholding state of affairs seems earlier than and after the completion of the Capital Improve.
Publicly obtainable data and danger elements
Detailed data in regards to the Firm, particularly regarding its exercise, its outcomes, prospects and the corresponding danger elements is supplied within the Firm's 2018 reference doc, registered with the AMF on April 12, 2019 below quantity R. 19 -Zero06 and which shall be up to date by the common registration doc of the Firm. The 2018 registration doc in addition to the opposite regulated data and the entire Firm's press releases could be seen on its web site (www.inventivapharma.com) and / or on the AMF web site (www.amf-france.org). As of February 7, 2020, the common registration doc might also be seen on the Firm's web site (www.inventivapharma.com) and / or on the AMF web site (www.amf-france.org). The general public's consideration is targeted on the chance elements regarding the Firm and its exercise, offered in chapter 2 of its 2018 registration doc, as up to date by the common registration doc. The admission prospectus submitted to the AMF for approval will even embrace the chance elements prone to affect the actions of the Firm. The conclusion of all or a part of these dangers may have a major unfavorable impact on the actions, the state of affairs, the monetary outcomes or the targets of the Firm.
This press launch doesn’t represent a prospectus below the Prospectus Laws (as outlined under) or a proposal to the general public.
About Inventiva
Inventiva is a biopharmaceutical firm specializing within the scientific growth of small, orally administered molecules for the remedy of illnesses with vital unmet medical wants within the areas of fibrosis, lysosomal overload and oncology.
With its experience and vital expertise within the growth of compounds concentrating on nuclear receptors, transcription elements and epigenetic modulation, Inventiva is at present growing two drug candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidoses (“MPS”) respectively, in addition to a portfolio of a number of applications within the preclinical stage.
Lanifibranor, its most superior drug candidate, is at present below growth for the remedy of sufferers with NASH, a persistent and progressive liver illness. Inventiva is at present evaluating lanifibranor in a Part IIb scientific trial for the remedy of this illness, for which there’s at present no permitted remedy.
Odiparcil is the second scientific candidate drug that Inventiva is growing for the remedy of sufferers with MPS, a gaggle of uncommon genetic illnesses. A Part I / II scientific trial in kids with MPS VI is being ready following the constructive outcomes of the Part IIa scientific trial carried out in grownup sufferers with the identical illness and printed in late 2019.
In parallel, Inventiva is within the course of of choosing a candidate drug in oncology for its program within the Hippo signaling pathway. As well as, the Firm has entered right into a strategic partnership with AbbVie within the space of autoimmune illnesses. AbbVie has began the scientific growth section of ABBV-157, a drug candidate for the remedy of the average to extreme type of psoriasis, ensuing from its collaboration with Inventiva. This partnership gives for the fee to Inventiva of milestone funds based mostly on the achievement of preclinical, scientific, regulatory and industrial targets in addition to royalties on the gross sales of merchandise developed inside the framework of this partnership.
The Firm has a scientific workforce of roughly 70 individuals with sturdy experience in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology in addition to in scientific growth. As well as, Inventiva has a library of roughly 240,00Zero molecules, of which roughly 60% are the property of the Firm, in addition to its personal laboratories and gear.
Inventiva is an organization listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com
contacts
inventiva
Frédéric Cren
President and CEO
info@inventivapharma.com
+33 three 80 44 75 00
Brunswick Group
Yannick Tetzlaff /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Warning
This doc and the knowledge it accommodates don’t represent a proposal to promote or purchase or a solicitation to promote or purchase securities of Inventiva Pharma S.A. (the “ Society “).
No communication or data regarding the problem by the Firm of its shares could also be disseminated to the general public in a rustic wherein a registration or approval requirement is required. No motion has been taken or shall be taken in any nation wherein such steps are required. The difficulty or subscription of shares could also be topic to particular authorized or regulatory restrictions in sure nations. The Firm assumes no accountability for any violation by any individual of those restrictions.
This doc doesn’t represent and shouldn’t be thought of as constituting a proposal to the general public, a proposal to buy or as supposed to solicit the curiosity of the general public with a view to an operation by public supply. The distribution of this doc could, in sure nations, be topic to particular rules. Individuals in possession of this doc should inform themselves of any native restrictions and adjust to them.
This doc constitutes a communication of a promotional nature and never a prospectus inside the which means of the Prospectus Laws (as outlined under), as transposed in every of the member states of the European Financial Space.
With regard to the member states of the European Financial Space (together with France) (the “ Member States ”), No motion has been taken and won’t be taken to allow the securities provided below this doc to be provided to the general public, making it essential to publish a prospectus in a single or different of the States Members. Consequently, the securities of the Firm can’t be provided and won’t be provided in any of the Member States, besides in accordance with the exceptions supplied for in article 1 (four) of the Prospectus Laws or in different circumstances not requiring publication by the Article 1 prospectus firmst of the Prospectus Laws and / or of the rules relevant on this Member State.
For the needs of this warning, the expression “supply to the general public” in reference to all actions of the Firm in any Member State means the communication, in no matter type and by no matter means, of ample data on the situations of the supply and the securities to be provided, in order to place an investor ready to determine to purchase or subscribe to securities, as presumably modified by the Member State. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129, and contains any related measure of transposition within the Member State.
This doc doesn’t represent a proposal to the general public in France and the securities referred to on this doc can solely be provided or offered in France, in accordance with article L. 411-2 of the Financial and Monetary Code, solely to certified traders performing on personal account below the Prospectus Laws. As well as, by advantage of the authorization granted by the final assembly of the Firm on January 18, 2019, solely individuals falling into the classes specified within the fifth decision of this common assembly can subscribe to the supply.
This doc shouldn’t be distributed, immediately or not directly, in the US. This doc doesn’t represent a proposal of securities or any solicitation to buy securities of the Firm in the US or in every other jurisdiction wherein such supply or solicitation could also be topic to restrictions. Firm securities might not be provided or offered in the US with out registration or an exemption from registration below the U.S. Securities Act of 1933, as amended (the “ Securities Act “). The Firm's securities haven’t been and won’t be registered below the Securities Act, and the Firm doesn’t intend to make a public providing of its securities in the US.
Distribution of this doc (this time period together with any type of communication) is topic to the restrictions set out in Part 21 Restrictions regarding “monetary promotion” of the Monetary Companies and Markets Act 2000 (” FMSA “). This doc is meant and supposed just for individuals who (i) are exterior the UK, (ii) have skilled funding expertise and are “funding professionals” as this time period is outlined within the article 19 (5) of the Monetary Companies and Markets Act 2000 (Monetary Promotion) Order 2005, as amended (” Order ”), (Iii) referred to in part 49 (2) (a) to (d) (“ excessive web value firms ”,“ unincorporated associations ”, and so on.) of the Order, and (iv) every other individual to which this doc could also be legally communicated (all these individuals talked about in (i), (ii), (iii) and (iv) being collectively known as the ” Certified Individuals “). This doc shouldn’t be used within the UK by individuals who aren’t Certified Individuals. Any funding linked to this doc could solely be provided or concluded in the UK with Certified Individuals.
This doc shouldn’t be distributed, immediately or not directly, in the US, Canada, Australia or Japan.
